Company: DVAX
Filing Date: 2025-05-12
Form Type: DEFA14A
Source: 0000930413-25-001695
Chunk: 5

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-05-12
Form: DEFA14A
Chunk 5
---
 delivering value for our stockholders, our future growth, potential of our differentiated
technology, the timing of initiation and completion of clinical trials and expected results, market share and size of the market, expected
product revenue, our business strategy and long-term performance. Actual results may differ materially from those set forth in this communication
due to the risks and uncertainties inherent in our business, including, the risk that circumstances surrounding or leading up to our 2025
Annual Meeting may change, risks relating to our ability to commercialize and supply HEPLISAV-B, the risks that market size or actual
demand for our products may differ from our expectations, risks related to the timing of completion and results of current clinical studies,
risks related to the development and pre-clinical and clinical testing of vaccines containing CpG 1018 adjuvant, and risks related to
the implementation of our long-term growth objectives, as well as other risks detailed in the "Risk Factors" section of our
Quarterly Report on Form 10-Q for the three months ended March 31, 2025 and any periodic filings made thereafter, as well as discussions
of potential risks, uncertainties and other important factors in our other filings with the U.S. Securities and Exchange Commission. These
forward-looking statements are made as of the date hereof, are qualified in their entirety by this cautionary statement and we undertake
no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes
available. Information on Dynavax's website at www.dynavax.com is not incorporated by reference in our current periodic reports with the
SEC.

Important Additional Information and Where to Find It

On April 17, 2025, the Company filed a definitive proxy statement
on Schedule 14A (the "Proxy Statement") and form of accompanying GOLD proxy card with the U.S. Securities and Exchange
Commission (the "SEC") in connection with its 2025 Annual Meeting and its solicitation of proxies for the Company's director
nominees and for other matters to be voted on. The Company may also file other relevant documents with the SEC regarding its
solicitation of proxies for the 2025 Annual Meeting. This communication is not a substitute for any proxy statement or other document
that the Company has filed or may file with the SEC in connection with any solicitation by the Company. STOCKHOLDERS OF THE
COMPANY ARE STRONGLY ENCOURAGED TO READ THE PROXY STATE